Heart failure & cardiomyopathies
Sodium-Glucose Cotransporter 2 Inhibitors are Associated with Reduced Risk of Mortality and Readmissions in Heart Failure
Authors' conclusion
This nationwide real-world study indicates that patients with HF, in which majority coexisted with diabetes mellitus, who received SGLT2i were statistically significantly associated with lower risk for all-cause mortality, cardiovascular mortality, cardiovascular mortality or HF readmissions, and all-cause readmissions, in line with the randomized trials assessing SGLT2i.
Study context
- Population
- Patients with heart failure (HF) in SwedeHF, index registration 3 September 2013 to 31 December 2020, on guideline-recommended therapy
- Participants
- 796 vs 22,405
- Exposure
- SGLT2i vs no SGLT2i
- SGLT2in = 796
- No SGLT2in = 22,405reference
- Outcome
- Mortality or readmissions
Methodological detailsnationwide registry (SwedeHF) linked with three national registers, adjusted Cox models
- Nationwide registry (SwedeHF) linked with three national registers
- Adjusted Cox models
Main finding
As reported in the abstract
SGLT2i vs No SGLT2iHazard ratio (95% CI)P value
All-cause mortality
0.61(0.48–0.79)
P < 0.0001CV mortality
0.29(0.17–0.50)
P < 0.0001CV mortality or HF readmission
0.89(0.80–1.00)
P = 0.046All-cause readmissions
0.90(0.81–0.99)
P = 0.038Observational data: associations, not effects.
Further findings
Diabetes cohort
- Similar results to the overall cohort
Original publication
Sodium-Glucose Cotransporter 2 Inhibitors are Associated with Reduced Risk of Mortality and Readmissions in Heart Failure. ESC Heart Fail. Published 27 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →